CL2021001884A1 - Compuestos heterocíclicos como antagonistas de la adenosina. - Google Patents

Compuestos heterocíclicos como antagonistas de la adenosina.

Info

Publication number
CL2021001884A1
CL2021001884A1 CL2021001884A CL2021001884A CL2021001884A1 CL 2021001884 A1 CL2021001884 A1 CL 2021001884A1 CL 2021001884 A CL2021001884 A CL 2021001884A CL 2021001884 A CL2021001884 A CL 2021001884A CL 2021001884 A1 CL2021001884 A1 CL 2021001884A1
Authority
CL
Chile
Prior art keywords
heterocyclic compounds
adenosine antagonists
compounds
adenosine
find
Prior art date
Application number
CL2021001884A
Other languages
English (en)
Inventor
Son Minh Pham
Jayakanth Kankanala
Pradeep S Jadhavar
Baban Mohan Mulik
Farha Khan
Sreekanth A Ramachandran
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2021001884A1 publication Critical patent/CL2021001884A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan compuestos de aminopirazina como moduladores de un receptor de adenosina. Los compuestos pueden encontrar uso como agentes terapéuticos para el tratamiento de enfermedades mediadas por una ruta de señalización de receptores acoplados a proteínas G y pueden encontrar uso particular en oncología.
CL2021001884A 2019-01-18 2021-07-15 Compuestos heterocíclicos como antagonistas de la adenosina. CL2021001884A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962794537P 2019-01-18 2019-01-18
US201962796046P 2019-01-23 2019-01-23

Publications (1)

Publication Number Publication Date
CL2021001884A1 true CL2021001884A1 (es) 2022-03-04

Family

ID=71609717

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001884A CL2021001884A1 (es) 2019-01-18 2021-07-15 Compuestos heterocíclicos como antagonistas de la adenosina.

Country Status (13)

Country Link
US (2) US11306071B2 (es)
EP (1) EP3911323A4 (es)
JP (1) JP2022517419A (es)
KR (1) KR20210116550A (es)
CN (1) CN113924095A (es)
AU (1) AU2020208644A1 (es)
BR (1) BR112021013936A2 (es)
CA (1) CA3126702A1 (es)
CL (1) CL2021001884A1 (es)
IL (1) IL284767A (es)
MX (1) MX2021008650A (es)
SG (1) SG11202107810WA (es)
WO (1) WO2020150674A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2022169897A1 (en) * 2021-02-03 2022-08-11 Nuvation Bio Inc. Crystalline forms of a cyclin-dependent kinase inhibitor
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
GEP20084341B (en) 2003-02-26 2008-03-25 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors
CN1791580A (zh) 2003-03-24 2006-06-21 麦克公司 联芳基取代的6元杂环钠通道阻滞剂
EP1678160A1 (en) 2003-10-27 2006-07-12 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
CA2544191A1 (en) 2003-11-04 2005-05-26 Merck & Co., Inc. Substituted naphthyridinone derivatives
ES2309486T3 (es) 2003-11-27 2008-12-16 Yul Anderson Metodo y auricular tubular vsr.
CN1938296A (zh) * 2004-04-01 2007-03-28 安斯泰来制药有限公司 作为腺苷拮抗剂的吡嗪衍生物及其制药用途
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
SI2252597T1 (sl) * 2008-02-01 2014-07-31 Akinion Pharmaceuticals Ab Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze
US7928248B2 (en) 2008-03-31 2011-04-19 Genentech, Inc. Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use
AU2010208480A1 (en) 2009-02-02 2011-07-28 Msd K.K. Inhibitors of Akt activity
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
CN102822150B (zh) 2010-02-05 2014-12-03 赫普泰雅治疗有限公司 1,2,4-三嗪-4-胺衍生物
SG186989A1 (en) 2010-07-14 2013-02-28 Novartis Ag Ip receptor agonist heterocyclic compounds
WO2012168358A1 (en) 2011-06-09 2012-12-13 Novaled Ag Compound for organic electronic device
AR089698A1 (es) 2012-01-13 2014-09-10 Novartis Ag Compuestos heterociclicos antagonistas del receptor ip
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
CA2903463A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
EP3521284B1 (en) 2013-03-15 2020-12-02 The Trustees of Columbia University in the City of New York Pyrazine compounds as map kinase modulators and uses thereof
CN105407888B (zh) 2013-06-21 2019-05-21 齐尼思表观遗传学有限公司 新双环溴结构域抑制剂
CN104341386A (zh) 2013-07-23 2015-02-11 中国科学院上海药物研究所 一类芳基杂环小分子化合物、其衍生物及其制备方法和用途
US9745297B2 (en) 2013-07-30 2017-08-29 Boehringer Ingelheim International Gmbh Compounds as modulators of RORC
SI3071203T1 (sl) 2013-11-18 2021-07-30 Forma Therapeutics, Inc. Sestavki tetrahidrokinolina, kot zaviralci BET bromodomene
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
AU2015222887B2 (en) 2014-02-28 2019-06-27 The Regents Of The University Of Michigan 9H-pyrimido[4,5-b]indoles and related analogs as BET bromodomain inhibitors
TWI735002B (zh) 2014-04-23 2021-08-01 美商英塞特公司 作為BET蛋白抑制劑之1H-吡咯并[2,3-c]吡啶-7(6H)-酮及吡唑并[3,4-c]吡啶-7(6H)-酮
MX2017003637A (es) 2014-09-19 2018-01-24 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh).
KR20170083136A (ko) 2014-11-18 2017-07-17 머크 샤프 앤드 돔 코포레이션 A2a 길항제 특성을 갖는 아미노피라진 화합물
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
WO2016203112A1 (en) 2015-06-16 2016-12-22 Orion Corporation Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
WO2017025918A1 (en) 2015-08-11 2017-02-16 Novartis Ag 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer
PE20181093A1 (es) 2015-09-21 2018-07-09 Plexxikon Inc Compuestos heterociclicos y usos de los mismos
KR20180052762A (ko) 2015-09-22 2018-05-18 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 브로모도메인 억제제로서 사용하기 위한 피리디논 디카르복스아미드
US10912776B2 (en) 2015-12-24 2021-02-09 Corvus Pharmaceuticals, Inc. Methods of treating cancer
JP7106462B2 (ja) 2016-07-01 2022-07-26 ジー１ セラピューティクス， インコーポレイテッド Ｎ－（ヘテロアリール）－ピロロ［３，２－ｄ］ピリミジン－２－アミンの合成
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
CA3028751A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
GB201612092D0 (en) 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
WO2018081863A1 (en) 2016-11-04 2018-05-11 University Of Wollongong 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF
NZ754731A (en) 2017-01-20 2023-02-24 Arcus Biosciences Inc Azolopyrimidine for the treatment of cancer-related disorders
SI3601296T1 (sl) 2017-03-30 2022-10-28 iTeos Belgium SA 2-okso-tiazolni derivati kot zaviralci A2A in spojine za uporabo pri zdravljenju raka
TWI801372B (zh) 2017-03-30 2023-05-11 比利時商艾特歐斯比利時有限公司 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法
CN107221611B (zh) 2017-06-15 2019-02-05 江西冠能光电材料有限公司 一种稳定易加工有机半导体材料及其有机发光器件应用
WO2019002606A1 (en) 2017-06-30 2019-01-03 Selvita S.A. ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS
EP3654982A4 (en) 2017-07-18 2021-04-14 Nuvation Bio Inc. 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
MX2020004837A (es) 2017-11-06 2020-08-13 Corvus Pharmaceuticals Inc Inhibidores de la vía de adenosina para el tratamiento del cáncer.
WO2019096322A1 (zh) 2017-11-20 2019-05-23 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
EP3723754A4 (en) 2017-12-13 2021-05-19 Merck Sharp & Dohme Corp. IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
CA3086054A1 (en) 2017-12-20 2019-06-27 Betta Pharmaceuticals Co., Ltd Compound functioning as bromodomain protein inhibitor, and composition
WO2019134539A1 (zh) 2018-01-05 2019-07-11 四川科伦博泰生物医药股份有限公司 二氢吡唑酮并嘧啶类化合物及其制备方法和用途
WO2019141131A1 (zh) 2018-01-16 2019-07-25 中国科学院上海药物研究所 溴结构域抑制剂化合物及其用途
EA202091450A1 (ru) 2018-01-29 2021-01-14 Бета Фарма, Инк. Производные 2h-индазола в качестве ингибиторов cdk4 и cdk6 и их терапевтические применения
CA3089159A1 (en) 2018-02-06 2019-08-15 Jiangsu Hengrui Medicine Co., Ltd. Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof
EP3752600A1 (en) 2018-02-13 2020-12-23 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
CN111989313A (zh) 2018-02-15 2020-11-24 杭州阿诺生物医药科技有限公司 A2a和/或a2b受体拮抗剂
US11479555B2 (en) 2018-02-23 2022-10-25 Newave Pharmaceutical Inc. Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase
PE20211001A1 (es) 2018-02-27 2021-06-01 Incyte Corp Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
CA3088997A1 (en) 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
EP3762385A4 (en) 2018-03-09 2021-11-24 Recurium IP Holdings, LLC SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDINE-3-ONE
US11220510B2 (en) 2018-04-09 2022-01-11 Incyte Corporation Pyrrole tricyclic compounds as A2A / A2B inhibitors
BR112021002895A2 (pt) * 2018-08-17 2021-05-11 Dizal (Jiangsu) Pharmaceutical Co., Ltd compostos de pirazina e seus usos
TWI820209B (zh) 2018-09-12 2023-11-01 大陸商迪哲（江蘇）醫藥股份有限公司 三唑并－嘧啶化合物及其用途
EP3911325A4 (en) 2019-01-18 2022-10-12 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
CA3126703A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Compounds and uses thereof
WO2020150676A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
WO2021146629A1 (en) 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
WO2021146631A1 (en) 2020-01-17 2021-07-22 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists

Also Published As

Publication number Publication date
AU2020208644A1 (en) 2021-08-26
SG11202107810WA (en) 2021-08-30
MX2021008650A (es) 2021-11-03
US11306071B2 (en) 2022-04-19
US20220298142A1 (en) 2022-09-22
EP3911323A4 (en) 2022-11-16
IL284767A (en) 2021-08-31
CA3126702A1 (en) 2020-07-23
JP2022517419A (ja) 2022-03-08
EP3911323A1 (en) 2021-11-24
CN113924095A (zh) 2022-01-11
BR112021013936A2 (pt) 2021-09-21
KR20210116550A (ko) 2021-09-27
US20200231570A1 (en) 2020-07-23
WO2020150674A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
MX2020000690A (es) Compuestos heterociclicos como antagonistas de adenosina.
CL2021001884A1 (es) Compuestos heterocíclicos como antagonistas de la adenosina.
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
ECSP18094857A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
EA201791239A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
CL2016001983A1 (es) Compuestos aza bicíclicos como agonistas del receptor muscarínico m1 y/o m4
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CO7310529A2 (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
NZ737399A (en) Ccr2 modulators
PA8576901A1 (es) Moduladores del receptor de glucocorticoides
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
ECSP045203A (es) Cicloalcanindoles con sustitución con flúor y su uso como antagonistas del receptor prostaglandina d2
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
MX2020000693A (es) Compuestos de 1,8-naftiridinona, y usos de los mismos.
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
PA8657501A1 (es) Derivados de piperida y su uso como agentes antiinflamatorios
ECSP088279A (es) Ciclopropil aminas como moduladores del receptor de histamina h3
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CO2020002576A2 (es) Compuestos de indazol como potenciadores alostericos mglur4, composiciones y métodos de tratamiento de la disfunción neurológica
CL2021002521A1 (es) Compuestos heteocíclicos y sus usos.
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa